Intrauterine insemination with recombinant or urinary human chorionic gonadotropin: A prospective randomized trial.
OBJECTIVE
Our aim was to compare the efficacy and safety of recombinant and urinary human chorionic gonadotropin (rhCG and uhCG, respectively) for the induction of follicle maturation in women undergoing intrauterine insemination (IUI).


METHODS
Patients were randomized to receive rhCG or uhCG. IUI was carried out 24 h (day 1) and 48 h (day 2) after hCG administration, except for all cases in which ovulation occurred after 24 h.


RESULTS
The two treatments were comparable in terms of progesterone levels on day 7 and day 12. Pregnancy rates were comparable between the treatment groups. Of the 64 women who received rhCG, 29.7% became pregnant; there were 16.7% clinical pregnancies and 3.1% biochemical pregnancies per started cycle, and an ongoing pregnancy rate of 93.7% was reported. Of the 61 patients who received uhCG, 24.6% became pregnant; there were 15.9% clinical pregnancies and 1.1% biochemical pregnancies per started cycle, and ongoing pregnancy rate was 92.9%. No adverse effects were noted in either group.


CONCLUSIONS
The recombinant products can be effectively used instead of urinary products; moreover, apart from the equivalent efficacy in ovulation induction and safety described in this study, it is necessary to consider the advantages provided by the recombinant form.
Lorusso
Filomenamila
F
Department of Gynaecology, Obstetrics and Neonatology, Gynaecology and Obstetric Unit A, University of Bari, Bari, Italy. milalorusso@yahoo.it
Palmisano
Marcella
M
Serratì
Giuseppe
G
Bassi
Emma
E
Lamanna
Giuseppina
G
Vacca
Margherita
M
Depalo
Raffaella
R
D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007315:Insemination, Artificial; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects
D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins